Nemaura Medical, Inc. · OTC:NMRD
Nemaura Medical — Technical Presentation (July 2018)
9 slides from Nemaura Medical's technical presentation, Jul 31, 2018
Slide 1: Interim Clinical Presentation of Comparative Home Use Study
Interim Clinical Presentation of Comparative Home use Study: A Prospective Single Centre Evaluation Nemaura Medical of the Accuracy and safety of the sugarBEAT® Non invasive Continuous Glucose Monitor (CGM) System: An Better Diagnostics for Life interim Evaluation NASDAQ: NMRD 31st July 2018 Author
Slide 2: Study Objective
Study Objective A EU based study to determine the safety and accuracy of the sugarBEAT® CGM to support FDA submission 2
Slide 3: Study Design
Prospective single arm, single centre study Abbott Freestyle Optimum Neo BGM used as reference for Home Study Portion Accuracy and safety assessed over on 75 patients over 525 wear days NEMAURA Venous blood samples used as reference for in-clinic portion of study MEDICAL
Slide 4: Study Methods
Study Methods –– –– –– –– –– –– –– 4
Slide 5: Baseline Characteristics
Baseline Characteristics Variable Age (Range and Mean) 20 years to 70 years, Mean age 45.2 Gender 12 Male, 13 Female Type 1/Type 2 12 Type 1/13 Type 2 5
Slide 6: Accuracy vs Glucose Range
Accuracy vs Glucose Range In-clinic portion of study 1-point calibration Range of Number of Paired points Paired points Paired points Paired points Paired points Glucose Levels paired (BGM- within ±15% /15 within ±20% /20 within ±25% /25 within ±30% /30 within ±40% /40 (mMol/L) CGM) points Overall 1
Slide 7: Interim Comparative MARD for home study phase as Primary Accuracy Metric
Interim Comparative MARD for home study phase as Primary Accuracy Metric Device Number of Paired Data Nominal MARD Reference BGM Daily Finger Stick Subjects Points with BGM Calibrations Senseonics Nova Biomedical 23 829 14.80% 2 Eversense* StatStrip Xpress Nova Biomedical Dexcom G5* 23 829 16.30% 2
Slide 8: Safety Evaluation
Safety Evaluation Past Studies Current Studies –– –– –– 8
Slide 9: Conclusion
Conclusion The interim analysis indicates the home portion of the study shows accuracy levels, measured using overall nominal MARD, as being comparable to independently published data on the three market leading CGM’s. 9